Clinical Challenges & Core Clinical Benefits
Clinical Challenges
Difficult Clinical Differential Diagnosis
Upper respiratory tract infections share highly overlapping symptoms including fever, cough, sore throat and dyspnea, particularly in severe inpatients and immunocompromised populations. Mixed infections are common in critical cases, making empirical judgment unreliable and targeted treatment difficult to implement.
Limited Traditional Detection Capability
Conventional microbial culture takes 3–7 days with a positive rate of only 40%–60%, while single-target PCR assays have narrow pathogen coverage. Neither method can simultaneously detect viruses, atypical pathogens and bacteria, easily leading to missed diagnosis, delayed treatment and irrational antibiotic use.
Cumbersome & Inefficient Conventional Workflow
Traditional nucleic acid testing requires dedicated PCR laboratories and well-trained technicians, with multi-step manual operations and long turnaround times. It cannot meet the urgent diagnostic demands of inpatient wards and intensive care units.
Precise Etiological Diagnosis for Severe Care
A single nasopharyngeal swab enables simultaneous detection of 26 respiratory pathogens covering viruses, atypical pathogens and pathogenic bacteria. One-time clear etiological identification guides precise targeted therapy, reduces unnecessary empirical antibiotic use, and shortens hospital length of stay.

Reliable Co-Infection & Outbreak Management Support
Accurately identifies mixed infections of multiple pathogens, providing critical evidence for individualized treatment of severe and immunocompromised patients, and supporting rapid screening and management of nosocomial respiratory infection outbreaks.
High-Efficiency Testing for Inpatient Demands
Compatible with the Multi-Disc (Model: CQ-0404) fully automated nucleic acid analyzer, the assay delivers complete results in ~80 minutes. The platform supports parallel testing of 4 samples per run, greatly improving batch detection efficiency and saving the golden diagnostic window for critically ill patients.
Minimal Hands-on Operation | Fully Automated Workflow
Nucleic acid extraction reagents and lyophilized PCR reagents are pre-embedded on the chip. After sample loading, nucleic acid purification, amplification and result analysis are completed fully automatically, with no manual extraction required. No professional PCR laboratory or specialized operator is needed, significantly lowering the testing threshold.

Unified High Sensitivity & Specificity
Unified Limit of Detection (LOD) of 500 copies/mL for all 26 targets, enabling early detection even at low viral/bacterial loads. Clinical validation data shows positive agreement of 94.12%–100.00%, negative agreement above 99.61%, and overall concordance ≥99.45%, ensuring stable and reliable results.
Single-Cartridge Built-In Quality Control
An on-chip internal control monitors the full fluidic flow and PCR reaction process, effectively eliminating false negative results and guaranteeing the testing quality of each individual cartridge.
Wide Storage & Transportation Tolerance
The kit can be stored and transported at 4–28°C with no cold chain required, and has a 12-month shelf life, reducing logistics costs and inventory management pressure for hospital customers.